Abstract
Probiotics are effective in reducing necrotising enterocolitis in preterm infants, but routine use is not generally adopted. We describe a safety issue concerning contamination by pathogenic bacteria and missing of labelled strains in a probiotic product widely used in neonatal care. We recommend all centres using probiotics in the care of vulnerable patients to consider product safety checks in addition to the quality reports of manufacturers. Meanwhile, clinicians and manufacturers should collaborate to define quality standards for probiotic products in clinical settings as long as specific international regulations are lacking.
Original language | English |
---|---|
Pages (from-to) | 276-279 |
Number of pages | 4 |
Journal | Acta paediatrica (Oslo, Norway |
Volume | 109 |
Issue number | 2 |
DOIs | |
Publication status | Published - 1 Feb 2020 |
Keywords
- Infloran
- contamination
- necrotising enterocolitis
- probiotics
- safety